IPSC — Century Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1850119 ·
Last close
$1.37
Market Cap
$248.79M
52W High
$3.04
52W Low
$0.45
ADV30
930,732
Next earnings
2026-11-12
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -25,206,000 -23,453,000 262,626,000 45,016,000 52,659,000
Jun 2026 0 — -25,382,000 -34,550,000 287,006,000 49,642,000 54,661,000
Mar 2026 0 — -23,684,000 -21,645,000 326,553,000 51,048,000 61,809,000
Dec 2025 0 — -20,651,000 -19,171,000 223,704,000 61,853,000 64,768,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-83,401,000
Investing CF
$-54,961,000
Financing CF
$127,063,000
CapEx
$-2,008,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-871,565,000
Inventory
—
Receivables
$667,000
ST Investments
$72,185,000
EBIT TTM
$-94,923,000
Pretax Income TTM
$-98,887,000
Interest Exp TTM
—
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-92,245,000
Free Cash Flow
$-57,537,376
Enterprise Value
$219,926,048
Total Cash
$117,201,000
Total Debt
$37,492,000
Shares Out
181,597,002
Trailing EPS
$-0.64
Book Value
$1.16
ROE
-51.2%
ROA
-25.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 109,164,000 -10,506,000 -9,580,000 223,704,000 64,768,000 158,936,000 -103,876,000
Dec 2024 6,589,000 -133,810,000 -126,566,000 353,216,000 191,854,000 161,362,000 -110,135,000
Dec 2023 2,235,000 -125,181,000 -136,673,000 360,691,000 175,941,000 184,750,000 -88,348,000
Dec 2022 5,199,000 -123,831,000 -130,932,000 486,544,000 183,806,000 302,738,000 14,052,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-109,794,000
OpCashFlow TTM
—
Assets (Latest)
$287,006,000
Forward EPS
$-0.45

Peers — same industry

TickerNameMarket CapLastDaily %
PLX Protalix BioTherapeutics, Inc. $242.84M $2.88 —
OCGN Ocugen, Inc. $256.75M $0.76 —
ALLO Allogene Therapeutics, Inc. $257.08M $0.74 —
LXEO Lexeo Therapeutics, Inc. $234.24M $2.86 —
SABS SAB Biotherapeutics, Inc. $265.76M $2.95 —

News headlines (Yahoo Finance, 1h cache)

Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
2026-11-12 12:05 · Yahoo
Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
2026-10-14 12:05 · Yahoo
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
2026-10-02 12:05 · Yahoo
Century Therapeutics Appoints Joseph Truitt to Board of Directors
2026-09-09 20:05 · Yahoo
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
2026-08-12 12:00 · Yahoo
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses
2026-07-14 10:33 · Yahoo
Century Therapeutics Reports First Quarter Financial Results and Business Updates
2026-05-13 12:00 · Yahoo
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
2026-04-30 20:05 · Yahoo
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation
2026-06-13 13:38 · Yahoo
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)
2026-05-01 08:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.